E-LIB Suche - Ergebnisse für: Lorusso, D.

1

84P Lack of diversity in clinical trials leading to Food an..:

Giudice, E. ; Sganga, S. ; Rapisarda, E....
ESMO Open. 9 (2024) - p. 103544 , 2024

Link: https://doi.org/10.1016/..

2

5P Ovarian cancer ESCAT gene actionability: Cinderella wear..:

Camarda, F. ; Mastrantoni, L. ; Nero, C....
ESMO Open. 9 (2024) - p. 103505 , 2024

Link: https://doi.org/10.1016/..

3

N06 Self-care in patients affected by inflammatory bowel di..:

Napolitano, D ; Schiavoni, E ; Amatucci, V...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i2204-i2205 , 2024

Link: https://doi.org/10.1093/..

4

Promoting International Scientific Cooperation: the Role of..:

Vráblová, M. ; Bonetti, G. ; Henehan, G....
The EuroBiotech Journal. 8 (2024) 3 - p. 115-121 , 2024

Link: https://doi.org/10.2478/..

5

49MO Updated progression-free survival (PFS) in patients (p..:

Kristeleit, R. ; O'Malley, D. ; Lim, M-C....
ESMO Open. 9 (2024) - p. 103556 , 2024

Link: https://doi.org/10.1016/..

6

42MO Interpreting somatic POLE mutations in endometrial can..:

Trozzi, R. ; De Marco, L. ; Mastrantoni, L....
ESMO Open. 9 (2024) - p. 103590 , 2024

Link: https://doi.org/10.1016/..

7

47MO The risk index of early relapse defined by MiROvaR, a ..:

Bagnoli, M. ; De Cecco, L. ; Califano, D....
ESMO Open. 9 (2024) - p. 103554 , 2024

Link: https://doi.org/10.1016/..

8

102P A retrospective description of actionable mutations in..:

Camarda, F. ; Nero, C. ; Giacomini, F....
ESMO Open. 9 (2024) - p. 102328 , 2024

Link: https://doi.org/10.1016/..

9

MITO END-3: efficacy of avelumab immunotherapy according to..:

Pignata, S. ; Califano, D. ; Lorusso, D....
Annals of Oncology. 35 (2024) 7 - p. 667-676 , 2024

Link: https://doi.org/10.1016/..

10

46MO What are the predictors of the success of interval deb..:

Marchetti, C. ; Colomban, O. ; Fagotti, A....
ESMO Open. 9 (2024) - p. 103553 , 2024

Link: https://doi.org/10.1016/..

11

23O A randomized, phase III, double-blind study of chemorad..:

Xiang, Y. ; Hasegawa, K. ; Zhu, H....
ESMO Open. 9 (2024) - p. 103523 , 2024

Link: https://doi.org/10.1016/..

12

Olaparib plus bevacizumab first-line maintenance in ovarian..:

Ray-Coquard, I. ; Leary, A. ; Pignata, S....
Annals of Oncology. 34 (2023) 8 - p. 681-692 , 2023

Link: https://doi.org/10.1016/..

13

10P An adapted CGP-based model to interpret POLE mutations ..:

Trozzi, R. ; Ottaviani, M. ; Nero, C....
ESMO Open. 8 (2023) 1 - p. 101656 , 2023

Link: https://doi.org/10.1016/..

14

Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carb..:

Vergote, I. ; Van Nieuwenhuysen, E. ; Casado, A....
Gynecologic Oncology. 174 (2023) - p. 80-88 , 2023

Link: https://doi.org/10.1016/..

15

12P Tisotumab vedotin in recurrent or metastatic cervical c..:

Bini, M. ; Bogani, G. ; Coleman, R.L....
ESMO Open. 8 (2023) 1 - p. 100867 , 2023

Link: https://doi.org/10.1016/..